Both the Texas Senate and House of Representatives have passed legislation that would loosen restrictions on terminal patients accessing experimental drugs that aren't approved by the U.S. Food and Drug Administration. If signed into affect by Gov. Abbott the law would make Texas the 17th state to approve such measures.
What could the law change mean for the terminally ill in Texas? Will this affect scientific research?
Guest:
- Dr. Steve Weitman, Director for the Institute for Drug Development at the Cancer Therapy & Research Center, at the University of Texas Health Science Center
